Amanta Healthcare Ltd (AMANTA) — shareholding pattern, promoter holding, financials and share price
About Amanta Healthcare Ltd (AMANTA)
Amanta Healthcare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AMANTA and on the BSE under scrip code 544502. Its ISIN is INE084K01015.
Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products. [1]
Amanta Healthcare Limited is a fully integrated sterile liquids pharmaceutical manufacturer and marketer focused on Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), using ABFS and ISBM technologies from a WHO‑GMP certified facility in Gujarat, with a 47-product portfolio, 320 distributors, and exports to 21 countries.
The company is mid-inflection: FY25 revenues were INR275 crore and PAT turned positive to INR11 crore after prior losses, with a historical revenue CAGR of 11.8% (FY21–25); management targets a materially higher 20%+ CAGR over the next two years driven by capacity additions and product mix improvement.
Listed peers in Pharmaceuticals: Sigachi Industries Ltd, Anlon Healthcare Ltd, Anuh Pharma Ltd, Influx Healthtech Ltd, Kilitch Drugs (India) Ltd, Zim Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹180 a share on 10 Jul 2026, Amanta Healthcare Ltd (AMANTA) was valued at a price-to-earnings ratio of 46.97x against an industry P/E of 36.41x and a price-to-book of 7.25x on a book value of ₹24.82 per share as of Mar 2025. Solomo computes return on equity of 15.44% and return on capital employed of 13.94% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 46.97x
- Industry P/E
- 36.41x
- P/B
- 7.25x
- EPS (TTM)
- ₹3.83
- Book value / share
- ₹24.82
- ROE
- 15.44%
- ROCE
- 13.94%
- ROA
- 3.9%
- Debt / equity
- 2.12x
- Dividend yield
- 0%
- EBITDA margin
- 21.06%
- 52-week range
- ₹93.1 – ₹192
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Amanta Healthcare Ltd (AMANTA) reported revenue of ₹288 crore, net profit of ₹15 crore and earnings per share of ₹3.83. That compares with revenue of ₹275 crore and net profit of ₹10 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹76.99 crore and net profit ₹5.53 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 225 | 259 | 280 | 275 | 288 |
| Net profit (₹ cr) | 55 | -2 | 4 | 10 | 15 |
| EPS (₹) | 20.54 | -0.79 | 1.35 | 3.64 | 3.83 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 8.30% | 6.81% | -2.01% |
| Profit growth | - | -42.46% | 189.26% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 63.8% of Amanta Healthcare Ltd (AMANTA) (up 0.08 pp QoQ), foreign institutional investors (FII) hold 0.43% and domestic institutional investors (DII) hold 12.92%. Market capitalisation was ₹699 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2025.
Largest disclosed public shareholders in Jun 2026: Bandhan Small Cap Fund 5.33%, Perpetuity Health To Wealth (H2w) Rising Fund 1.83%, Finavenue Capital Trust - Finavenue Growth Fund 1.8%, Aarth Aif Growth Fund 1.74%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 63.8% | - | 0.43% | 12.92% | 36.2% |
| Mar 2026 | 63.72% | - | 0.85% | 12.88% | 36.28% |
| Dec 2025 | 63.56% | - | 1.1% | 11.24% | 36.44% |
| Sep 2025 | 63.56% | - | 1% | 11.34% | 36.44% |